AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02098499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 5mg IV
Study NCT02098499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: 10mg IV
Study NCT02098499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: 25mg IV
Study NCT02927704 — intervention group
Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) sample
Description: Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
Study NCT04274049 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
Study NCT04274049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
Study NCT02362516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Study NCT01772472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: 6 mg/kg intravenously every 3 weeks, 14 cycles
Study NCT01772472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: 3.6 mg/kg intravenously every 3 weeks, 14 cycles
Study NCT01746849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Study NCT01746849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lupron
Study NCT01746849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01746849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation (TBI)
Study NCT01746849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Study NCT01746849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01746849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT04134117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
Study NCT03100981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Mindfulness-Based Cognitive Therapy
Description: Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life.
Study NCT03100981 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient.
Study NCT01636063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
Study NCT01636063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
Study NCT04077671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF6467 active
Description: CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
Study NCT01611363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral
Study NCT01611363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT02454881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study NCT02454881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study NCT02814513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
Study NCT02814513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
Study NCT02814513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
Study NCT02814513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
Study NCT02814513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
Study NCT01503944 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-133
Description: 185 MBq
Study NCT02644122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF1126
Study NCT03511144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unity Knee™ TKR using measured resection
Description: Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
Study NCT03511144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unity Knee™ TKR using ligament balancing
Description: Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
Study NCT01503944 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-45
Description: 185-370 MBq
Study NCT02532933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Synthes Attune PS RP
Study NCT01891695 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 39.6 Gy radiation
Study NCT02801240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition support product
Description: Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
Study NCT00678054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
Study NCT01763216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Road Tour
Description: Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
Study NCT01763216 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Boatload of Crosswords
Description: Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
Study NCT03648060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital kinematic biofeedback system
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
Study NCT02662946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG- angiography
Description: Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
Study NCT02662946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No angiography
Description: Extension of resection based on subjective measures
Study NCT04565860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)
Description: Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations).
Study NCT02326025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study NCT02326025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV
Study NCT03236740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol-cyprosterone acetate
Description: Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
Study NCT03236740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
Study NCT04367220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic testing performed as per routine care
Study NCT01454622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Study NCT01454622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study NCT01265290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated 24 hours ECG Holter monitoring
Description: repeated 24 hours ECG Holter monitoring
Study NCT01265290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemetric ECG monitoring
Description: Telemetric ECG full disclosure monitoring with GSM technology
Study NCT03528993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise by hippotherapy device
Description: Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
Study NCT03528993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional rehabilitation
Description: Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
Study NCT03528993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
Study NCT03528993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: postural control exercises
Description: perturbation on four directions, weight bearing exercises on standing positions
Study NCT02278198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
Study NCT01401270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management
Description: Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
Study NCT00976092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 60 mg prasugrel as loading dose prior to PPCI
Study NCT00976092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
Study NCT02266927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent HFA
Study NCT02266927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPTINOSE™ FLUTICASONE
Study NCT02646618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Get Social
Description: Online-delivered weight loss intervention
Study NCT02646618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Group-delivered weight loss intervention
Study NCT02646618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
Study NCT00976092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg clopidogrel as loading dose before PPCI
Study NCT00976092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: i.v. bolus of 70-100 IU/kg body weight
Study NCT03578601 — intervention group
Intervention type: OTHER
Intervention: Thyroid surgery
Description: Patient undergoing thyroid surgery
Study NCT02348541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CollaGUARD
Study NCT03037411 — intervention group
Intervention type: DEVICE
Intervention: Peripheral stenting
Description: stent implantation during the index procedure
Study NCT01397474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPTFM
Description: Peripheral Perfusion Targeted Fluid Management
Study NCT00467259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Study NCT00467259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch, changed twice a week for 52 weeks
Study NCT04602455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Program through Heartfulness
Description: A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
Study NCT05076474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 60mg Cap
Description: Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
Study NCT05984446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-rTMS
Description: Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
Study NCT03630003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOCS
Description: The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform.
Study NCT03630003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-use interview
Description: The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
Study NCT05984446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-rTMS
Description: The sham condition will match the real-rTMS protocol, but a sham coil will be used.
Study NCT03404791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
Study NCT01716598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPS System
Description: TLD Therapy will be achieved bronchoscopically.
Study NCT01096264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SSI and SphygmoCor® evaluations
Description: * SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~* SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived.
Study NCT04003324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults
Description: Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
Study NCT02795884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intercalation therapy using pemetrexed, cisplatin and erlotinib
Description: During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
Study NCT02795884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine, cisplatin
Description: Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
Study NCT00872248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
Study NCT00872248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia
Description: Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
Study NCT01123174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALGOS algorithm of case management
Description: If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt.